No Data
No Data
Owning 56% in Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Means That Insiders Are Heavily Invested in the Company's Future
Ping An Securities: The updated policy for medical devices continues to be promoted, and domestic bidding and tendering are expected to significantly improve in the short term.
The update policy for medical field equipment is continuously advancing, and it is expected to gradually land in the second half of 2024. There is hope for significant improvement in domestic bidding and tendering in the short term.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): It is expected that the bid situation in the second half of the year will improve compared with the first half of the year.
In March of this year, the State Council released a notice regarding the "Action Plan for Promoting Large-Scale Equipment Updates and Old-for-New Consumer Goods", which specifically mentioned promoting the iterative upgrading of equipment and information technology facilities in medical and health institutions, encouraging medical institutions that meet the conditions to accelerate the upgrading and transformation of medical equipment, promoting the improvement of ward renovation in medical institutions, and filling in the gaps in ward environment and facilities. Since then, the company has paid close attention to the progress of the project, and various departments such as marketing, R&D, and production supply chain have also prepared related work.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ) will actively participate in the domestic centralized procurement of products such as ultrasonic knives and endoscopic staplers.
Mindray Bio-Medical Electronics (Shenzhen) Co., Ltd. (Stock code: 300760) recently stated during a specific survey that the company has basically completed the product layout of minimally invasive surgery for chest and abdomen with the listing of 4K+ fluorescence and 4K+3D thoracoabdominal endoscopy systems, as well as supporting medical devices and consumables such as electric knives, ultrasonic knives, energy platforms, and laparoscopic anastomotic devices. The company's product competitiveness has reached a leading level in China. Take the intelligent laparoscopic anastomotic device launched this year as an example. Wound anastomosis is a high-risk procedure in the surgical process, so the safety performance of the product is crucial. This is achieved through the product's built-in core technologies.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): Domestic market share of the company's chemiluminescence business this year is expected to surpass that of another imported brand.
Mindray Bio-Medical Electronics (300760.SZ) recently stated during a specific research survey that the chemiluminescence business, an important business that has driven the company's growth for several years in the past and for a considerable period in the future, has always been highly valued by Mindray for its development status. Mindray has continued to invest a high proportion of resources in this business in research and development, marketing, and the supply chain. One major investment by the company was the acquisition of Hybiome. In the nearly three years since the acquisition was completed, the integration of Hybiome has progressed smoothly with the launch of the industry-leading high-sensitivity myocardial protein hs-cTnl last year. This year, the international clinical chemistry and laboratory medicine
Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Could Become A Multi-Bagger
No Data